Literature DB >> 2444110

The third component of complement is transcribed and secreted by cultured human endothelial cells.

H B Warren1, P Pantazis, P F Davies.   

Abstract

Monotypic cultures of passaged human umbilical vein endothelial cells secrete C3 protein, which is specifically immunoprecipitable from cell lysates and conditioned medium. A transcript migrating at 5.3 kilobases hybridizes with a mouse-derived C3 DNA probe in parallel cultures of endothelial cells, hepatoma cells (HepG2), and freshly isolated human monocytes. Steady-state transcript levels were as follows: HepG2 cells, 1.0; monocytes, 0.05; endothelial cells, 0.01. These data suggest that C3, an indispensible component for activation of complement by both the classical and alternative pathways, is locally synthesized in the vascular bed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2444110      PMCID: PMC1899691     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  Modulation of monocyte complement synthesis by interferons.

Authors:  A O Hamilton; L Jones; L Morrison; K Whaley
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

Review 2.  Synthesis and secretion of complement proteins by macrophages.

Authors:  H R Colten; Y M Ooi; P J Edelson
Journal:  Ann N Y Acad Sci       Date:  1979       Impact factor: 5.691

Review 3.  The proteolytic activation systems of complement.

Authors:  K B Reid; R R Porter
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

4.  Biosynthesis and processing of a human precursor complement protein, pro-C3, in a hepatoma-derived cell line.

Authors:  K M Morris; G Goldberger; H R Colten; D P Aden; B B Knowles
Journal:  Science       Date:  1982-01-22       Impact factor: 47.728

5.  Human C'3: evidence for the liver as the primary site of synthesis.

Authors:  C A Alper; A M Johnson; A G Birtch; F D Moore
Journal:  Science       Date:  1969-01-17       Impact factor: 47.728

6.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation.

Authors:  S C Thornton; S N Mueller; E M Levine
Journal:  Science       Date:  1983-11-11       Impact factor: 47.728

7.  Suppression of T lymphocyte functions by human C3 fragments. I. Inhibition of human T cell proliferative responses by a kallikrein cleavage fragment of human iC3b.

Authors:  J L Meuth; E L Morgan; R G DiSipio; T E Hugli
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.

Authors:  A E Davis; R A Harrison; P J Lachmann
Journal:  J Immunol       Date:  1984-04       Impact factor: 5.422

9.  Quantitative determination of histone modification. H2A acetylation and phosphorylation.

Authors:  P Pantazis; W M Bonner
Journal:  J Biol Chem       Date:  1981-05-10       Impact factor: 5.157

10.  Biosynthesis and processing of pro-C3, a precursor of the third component of complement in rat hepatocytes: effect of secretion-blocking agents.

Authors:  Y Misumi; N Takami; Y Ikehara
Journal:  FEBS Lett       Date:  1984-09-17       Impact factor: 4.124

View more
  17 in total

1.  LDL and HDL transfer rates across peripheral microvascular endothelium agree with those predicted for passive ultrafiltration in humans.

Authors:  C Charles Michel; M Nazeem Nanjee; Waldemar L Olszewski; Norman E Miller
Journal:  J Lipid Res       Date:  2014-11-14       Impact factor: 5.922

2.  Homozygous hereditary C3 deficiency due to a premature stop codon.

Authors:  Edimara Da Silva Reis; Gisele Vanessa Baracho; Adriana Sousa Lima; Chuck S Farah; Lourdes Isaac
Journal:  J Clin Immunol       Date:  2002-11       Impact factor: 8.317

Review 3.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

4.  Cis- and trans-acting elements required for constitutive and cytokine-regulated expression of the mouse complement C3 gene.

Authors:  N Kawamura; L Singer; R A Wetsel; H R Colten
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

5.  Peroxisome proliferator-activated receptor α positively regulates complement C3 expression but inhibits tumor necrosis factor α-mediated activation of C3 gene in mammalian hepatic-derived cells.

Authors:  Denis A Mogilenko; Igor V Kudriavtsev; Vladimir S Shavva; Ella B Dizhe; Ekaterina G Vilenskaya; Alexander M Efremov; Andrej P Perevozchikov; Sergey V Orlov
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

6.  Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and Toll-like receptor 4 activation in human macrophages.

Authors:  Denis A Mogilenko; Igor V Kudriavtsev; Andrey S Trulioff; Vladimir S Shavva; Ella B Dizhe; Boris V Missyul; Alexander V Zhakhov; Alexander M Ischenko; Andrej P Perevozchikov; Sergey V Orlov
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

7.  Cellular specificity of murine renal C3 expression in two models of inflammation.

Authors:  B H Ault; H R Colten
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

8.  Nonsense-codon-mediated decay in human hereditary complement C3 deficiency.

Authors:  Edimara S Reis; Victor Nudelman; Lourdes Isaac
Journal:  Immunogenetics       Date:  2003-11-25       Impact factor: 2.846

9.  C3 synthesis by A549 alveolar epithelial cells is increased by interferon-gamma and dexamethasone.

Authors:  L D Hill; L Sun; M P Leuschen; T L Zach
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

10.  Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells.

Authors:  R A Brooimans; A P Stegmann; W T van Dorp; A A van der Ark; F J van der Woude; L A van Es; M R Daha
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.